Chemokine - Chemokine receptors in cancer immunotherapy

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 109-127

  Stewart, Trina J ^a   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Anticancer; Chemokine; Immunotherapy; Target; Tumor

Indexed keywords

CCL16 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; CXCL9 CHEMOKINE; DNA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; SIMVASTATIN; STROMAL CELL DERIVED FACTOR 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER GROWTH; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; CELL COMMUNICATION; CELL MOVEMENT; CHEMOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; ORGAN SPECIFICITY; RECEPTORS, CHEMOKINE; TUMOR ESCAPE;

EID: 77953437752     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.109     Document Type: Review

References (169)

1. Zlotnik A: Chemokines and cancer. Int. J. Cancer 119, 2026-2029 (2006).
2. Moser B, Wolf M, Walz A, Loetscher P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75-84 (2004). (Pubitemid 38167488)
3. Le Y, Zhou Y, Iribarren P, Wang J: Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell. Mol. Immunol. 1, 95-104 (2004).
4. Murdoch C, Finn A: Chemokine receptors and their role in inflammation and infectious diseases. Blood 95, 3032-3043 (2000). (Pubitemid 30321151)
5. Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A: The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev. 177, 141-149 (2000).
6. Dieu MC, Vanbervliet B, Vicari A et al.: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386 (1998).
7. Kim CH, Broxmeyer HE: Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J. Leukoc. Biol. 65, 6-15 (1999).
8. Ebert LM, Schaerli P, Moser B: Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol. Immunol. 42, 799-809 (2005).
9. Caux C, Ait-Yahia S, Chemin K et al.: Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22, 345-369 (2000).
10. McColl SR: Chemokines and dendritic cells: a crucial alliance. Immunol. Cell Biol. 80, 489-496 (2002).
11. Balkwill F: Cancer and the chemokine network. Nat. Rev. Cancer 4, 540-550 (2004).
12. Homey B, Muller A, Zlotnik A: Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2, 175-184 (2002).
13. Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E: The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res. 68, 4701-4708 (2008).
14. Belperio JA, Keane MP, Arenberg DA et al.: CXC chemokines in angiogenesis. J. Leukoc. Biol. 68, 1-8 (2000).
15. Salcedo R, Wasserman K, Young HA et al.: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am. J. Pathol. 154, 1125-1135 (1999).
16. Bernardini G, Spinetti G, Ribatti D et al.: I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 96, 4039-4045 (2000).
17. + endothelial cells. J. Immunol. 166, 7571-7578 (2001). (Pubitemid 32525638)
18. Tse KP, Tsang NM, Chen KD et al.: MCP-1 Promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin. Cancer Res. 13, 6320-6326 (2007).
19. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R: Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin. Chem. 51, 452-455 (2005).
20. Azenshtein E, Luboshits G, Shina S et al.: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62, 1093-1102 (2002). (Pubitemid 34160293)
21. Manes S, Mira E, Colomer R et al.: CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J. Exp. Med. 198, 1381-1389 (2003).
22. Zou W, Machelon V, Coulomb-L'Hermin A et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339-1346 (2001).
23. Nahon P, Sutton A, Rufat P et al.: Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J. Gastroenterol. 14, 713-719 (2008).
24. Savage SA, Abnet CC, Mark SD et al.: Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 13, 2251-2257 (2004).
25. Vairaktaris E, Yapijakis C, Serefoglou Z et al.: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur. J. Surg. Oncol. 33, 504-507 (2007).
26. Ben Nasr H, Chahed K, Mestiri S, Bouaouina N, Snoussi K, Chouchane L: Association of IL-8 (-251)T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum. Immunol. 68, 761-769 (2007).
27. Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN, Chouchane L: Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum. Immunol. 67, 13-21 (2006). ■ Along with [28], two recent papers that report a correlation of CXCL8 polymorphisms and breast cancer.
28. Kamali-Sarvestani E, Aliparasti MR, Atefi S: Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma 54, 484-489 (2007). ■ Along with [27], two recent papers that report a correlation of CXCL8 polymorphisms and breast cancer.
29. Hassan S, Baccarelli A, Salvucci O, Basik M: Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin. Cancer Res. 14, 446-454 (2008).
30. Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G, Medeiros R: CXCL12 -3′A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol. Immunother. 55, 639-643 (2006).
31. Dommange F, Cartron G, Espanel C et al.: CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J. 20, 1913-1915 (2006).
32. de Oliveira CE, Cavassin GG, Perim Ade L et al.: Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J. Clin. Lab. Anal. 21, 49-54 (2007).
33. Vairaktaris E, Vylliotis A, Spyridonodou S et al.: A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. AntiCancer Res. 28, 271-275 (2008). (Pubitemid 351362912)
34. Hirata H, Hinoda Y, Kikuno N et al.: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin. Cancer Res. 13, 5056-5062 (2007).
35. de Oliveira Cavassin GG, De Lucca FL, Delgado Andre N et al.: Molecular investigation of the stromal cell-derived factor-1 chemokine in lymphoid leukemia and lymphoma patients from Brazil. Blood Cells Mol. Dis. 33, 90-93 (2004).
36. Lowe SW, Cepero E, Evan G: Intrinsic tumour suppression. Nature 432, 307-315 (2004).
37. Soengas MS: Cancer: Ins and outs of tumour control. Nature 454, 586-587 (2008). ■■ Outlines and compares three recent papers on tumor senescence pathways and their role in tumor progression.
38. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001).
39. Coppe JP, Kauser K, Campisi J, Beausejour CM: Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 281, 29568-29574 (2006).
40. Xue W, Zender L, Miething C et al.: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007). (Pubitemid 46232886)
41. Acosta JC, O'Loghlen A, Banito A et al.: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018 (2008). (Pubitemid 351795610)
42. Kuilman T, Michaloglou C, Vredeveld LC et al.: Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031 (2008). (Pubitemid 351787746)
43. Maxwell PJ, Gallagher R, Seaton A et al.: HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26, 7333-7345 (2007). (Pubitemid 350115971)
44. Wislez M, Fujimoto N, Izzo JG et al.: High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 66, 4198-4207 (2006).
45. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR: Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-374 (2008). (Pubitemid 351191995)
46. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54, 3242-3247 (1994). (Pubitemid 24208936)
47. Cabioglu N, Yazici MS, Arun B et al.: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 11, 5686-5693 (2005).
48. Ding Y, Shimada Y, Maeda M et al.: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9, 3406-3412 (2003).
49. Gunther K, Leier J, Henning G et al.: Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int. J. Cancer 116, 726-733 (2005). (Pubitemid 41099704)
50. Mashino K, Sadanaga N, Yamaguchi H et al.: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62, 2937-2941 (2002). (Pubitemid 34525782)
51. Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer 105, 186-189 (2003).
52. Muller A, Homey B, Soto H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). (Pubitemid 32225831)
53. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl Cancer Inst. 93, 1638-1643 (2001). (Pubitemid 33094871)
54. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 14, 171-179 (2004). ■■ Highlights the importance of the CXCR4-CXCL12 axis in metastasis.
55. Salvucci O, Bouchard A, Baccarelli A et al.: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat. 97, 275-283 (2006).
56. Li YM, Pan Y, Wei Y et al.: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459-469 (2004). (Pubitemid 39469982)
57. Kang Y, Siegel PM, Shu W et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003). (Pubitemid 36808649)
58. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P et al.: NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278, 21631-21638 (2003).
59. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG: Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 7, R402-10 (2005).
60. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33, 369-385 (2006).
61. Allinen M, Beroukhim R, Cai L et al.: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32 (2004). (Pubitemid 38903159)
62. Orimo A, Gupta PB, Sgroi DC et al.: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005). (Pubitemid 40692295)
63. Zagzag D, Krishnamachary B, Yee H et al.: Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178-6188 (2005). (Pubitemid 40994403)
64. Polyak K, Hahn WC: Roots and stems: stem cells in cancer. Nat. Med. 12, 296-300 (2006).
65. Schabath H, Runz S, Joumaa S, Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell. Sci. 119, 314-325 (2006).
66. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98, 1652-1658 (2007). (Pubitemid 47487897)
67. Kucia M, Reca R, Miekus K et al.: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894 (2005). (Pubitemid 41170944)
68. Vicari AP, Treilleux I, Lebecque S: Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin. Cancer Biol. 14, 161-169 (2004).
69. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274 (2005). ■ How tumor-induced immunosuppression should be considered in the design of therapeutic strategies.
70. Murakami T, Cardones AR, Finkelstein SE et al.: Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med. 198, 1337-1347 (2003).
71. Simonetti O, Goteri G, Lucarini G et al.: Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur. J. Cancer 42, 1181-1187 (2006).
72. Kohrgruber N, Groger M, Meraner P et al.: Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol. 173, 6592-6602 (2004). (Pubitemid 39541042)
73. Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M: Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102, 789-794 (2003). (Pubitemid 36917764)
74. Tharp WG, Yadav R, Irimia D et al.: Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo. J. Leukoc. Biol. 79, 539-554 (2006).
75. Vianello F, Papeta N, Chen T et al.: Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J. Immunol. 176, 2902-2914 (2006). (Pubitemid 43306951)
76. Lee CH, Kakinuma T, Wang J et al.: Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol. Cancer Ther. 5, 2592-2599 (2006).
77. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78 (2004).
78. Allavena P, Sica A, Solinas G, Porta C, Mantovani A: The inflammatory microenvironment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66, 1-9 (2008).
79. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25, 315-322 (2006). (Pubitemid 44922352)
80. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002). (Pubitemid 34189413)
81. Ueno T, Toi M, Saji H et al.: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289 (2000).
82. Dehqanzada ZA, Storrer CE, Hueman MT et al.: Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin. Cancer Res. 12, 478-486 (2006).
83. Sica A, Saccani A, Bottazzi B et al.: Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol. 164, 733-738 (2000). (Pubitemid 30043695)
84. Wang HY, Wang RF: Regulatory T cells and cancer. Curr. Opin. Immunol. 19, 217-223 (2007).
85. + regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs 8, 1002-1008 (2007).
86. Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI: Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev. Mol. Med. 9, 1-20 (2007). ■■ How immune responses can influence tumor progression and mechanisms whereby tumors escape recognition and destruction. Includes a brief review on the pros and cons of some preclinical models.
87. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004). (Pubitemid 38134298)
88. Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
89. Ishida T, Ishii T, Inagaki A et al.: Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66, 5716-5722 (2006). (Pubitemid 43927124)
90. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398-7405 (2006).
91. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB: Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57, 123-131 (2008).
92. + regulatory T cells in gastric cancer. Int. J. Cancer 122, 2286-2293 (2008). (Pubitemid 351542333)
93. Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 97, 1139-1146 (2006). (Pubitemid 44430638)
94. Baumforth KR, Birgersdotter A, Reynolds GM et al.: Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol. 173, 195-204 (2008).
95. Gabrilovich DI, Bronte V, Chen SH et al.: The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67(1), 425; author reply 426 (2007). (Pubitemid 46142802)
96. Serafini P, Borrello I, Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65 (2006).
97. Bobe P, Benihoud K, Grandjon D, Opolon P, Pritchard LL, Huchet R: Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood 94, 1028-1037 (1999). (Pubitemid 29361835)
98. + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176, 2085-2094 (2006). (Pubitemid 43201655)
99. + cells. J. Immunol. 161, 5313-5320 (1998). (Pubitemid 28519091)
100. Schleifer KW, Mansfield JM: Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol. 151, 5492-5503 (1993).
101. Serafini P, De Santo C, Marigo I et al.: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72 (2004).
102. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). (Pubitemid 39361441)
103. Talmadge JE: Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13, 5243-5248 (2007). ■ Outlines the roles that myeloid-derived suppressor cells can have on suppressing immune responses and highlights their relevance in anticancer therapy design.
104. Stewart TJ, Lutsiak ME, Abrams SI: Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. Cancer Invest. 26, 237-249 (2008).
105. Almand B, Clark JI, Nikitina E et al.: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001). (Pubitemid 32038493)
106. Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756-4760 (2001). (Pubitemid 32691887)
107. Zea AH, Rodriguez PC, Atkins MB et al.: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005).
108. Filipazzi P, Valenti R, Huber V et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007).
109. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13, 721S-726S (2007).
110. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB: Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J. Immunol. 170, 5064-5074 (2003).
111. Rodriguez PC, Quiceno DG, Zabaleta J et al.: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849 (2004). (Pubitemid 39095585)
112. Apolloni E, Bronte V, Mazzoni A et al.: Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165, 6723-6730 (2000). (Pubitemid 32001135)
113. Lin EY, Gouon-Evans V, nguyen AV, Pollard JW: The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7, 147-162 (2002).
114. Gabrilovich D: Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
115. Melani C, Chiodoni C, Forni G, Colombo MP: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003). (Pubitemid 37122391)
116. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I: High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64, 6337-6343 (2004). (Pubitemid 39129439)
117. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026 (2007). (Pubitemid 47621253)
118. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67, 4507-4513 (2007). (Pubitemid 46815102)
119. Kuschert GS, Coulin F, Power CA et al.: Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38, 12959-12968 (1999). (Pubitemid 129515595)
120. Hecht I, Hershkoviz R, Shivtiel S et al.: Heparin-disaccharide affects T cells: inhibition of NF-κB activation, cell migration, and modulation of intracellular signaling. J. Leukoc. Biol. 75, 1139-1146 (2004).
121. Sigrist S, Oberholzer J, Bohbot A et al.: Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids. Immunology 111, 416-421 (2004). (Pubitemid 38482493)
122. Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O'Donnell J: Concentration-dependent roles for heparin in modifying lipopolysaccharide- induced activation of mononuclear cells in whole blood. Thromb. Haemost. 99, 570-575 (2008).
123. Mellor P, Harvey JR, Murphy KJ et al.: Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer 97, 761-768 (2007). ■ Recent report demonstrating the effects of heparin on tumor growth and metastasis. (Pubitemid 47396282)
124. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S: Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin. Cancer Res. 13, 1562-1570 (2007). (Pubitemid 46450448)
125. Kakkar AK, Levine MN, Kadziola Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22, 1944-1948 (2004).
126. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF: The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 14, 1071-1081 (2005).
127. Sutton A, Friand V, Papy-Garcia D et al.: Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol. Cancer Ther. 6, 2948-2958 (2007).
128. Proudfoot AE, Fritchley S, Borlat F et al.: The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 276, 10620-10626 (2001).
129. Veillard NR, Braunersreuther V, Arnaud C et al.: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188, 51-58 (2006). (Pubitemid 44142533)
130. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR: Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol. 28, 123-131 (2007). (Pubitemid 46975998)
131. Wang J, Loberg R, Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 25, 573-587 (2006). (Pubitemid 46071864)
132. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65, 967-971 (2005). (Pubitemid 40216458)
133. Rubin JB, Kung AL, Klein RS et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA 100, 13513-13518 (2003).
134. De Falco V, Guarino V, Avilla E et al.: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res. 67, 11821-11829 (2007).
135. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 12, 84-89 (2005).
136. Liang Z, Wu T, Lou H et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64, 4302-4308 (2004). (Pubitemid 38802437)
137. Yoon Y, Liang Z, Zhang X et al.: CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res. 67, 7518-7524 (2007). (Pubitemid 47206582)
138. Khan A, Greenman J, Archibald SJ: Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr. Med. Chem. 14, 2257-2277 (2007).
139. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63, 8360-8365 (2003).
140. Zhan W, Liang Z, Zhu A et al.: Discovery of small molecule CXCR4 antagonists. J. Med. Chem. 50, 5655-5664 (2007).
141. Kim SY, Lee CH, Midura BV et al.: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 25, 201-211 (2008).
142. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109, 2392-2404 (2007). (Pubitemid 46906457)
143. Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH: Gene modification strategies to induce tumor immunity. Immunity 22, 403-414 (2005). (Pubitemid 40545107)
144. Fushimi T, Kojima A, Moore MA, Crystal RG: Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383-1393 (2000).
145. Fushimi T, O'Connor TP, Crystal RG: Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res. 66, 3513-3522 (2006).
146. Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774-783 (2004).
147. Hillinger S, Yang SC, Zhu L et al.: EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J. Immunol. 171, 6457-6465 (2003). (Pubitemid 37532074)
148. Westermann J, nguyen-Hoai T, Baldenhofer G et al.: CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a Th1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 14, 523-532 (2007).
149. Howard OM, Dong HF, Shirakawa AK, Oppenheim JJ: LEC induces Chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood 96, 840-845 (2000).
150. Giovarelli M, Cappello P, Forni G et al.: Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164, 3200-3206. (2000). (Pubitemid 30148982)
151. Guiducci C, Di Carlo E, Parenza M et al.: Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol. 172, 4026-4036 (2004). (Pubitemid 38375214)
152. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C: Antitumor effects of the mouse chemokine 6chemokine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165, 1992-2000 (2000).
153. Sharma S, Stolina M, Luo J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558-4563 (2000). (Pubitemid 30238052)
154. Sharma S, Stolina M, Zhu L et al.: Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 61, 6406-6412 (2001). (Pubitemid 32783246)
155. Yang SC, Batra RK, Hillinger S et al.: Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 66, 3205-3213 (2006).
156. Yang SC, Hillinger S, Riedl K et al.: Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res. 10, 2891-2901 (2004).
157. Liu Y, Huang H, Saxena A, Xiang J: Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther. 9, 533-542 (2002). (Pubitemid 34569036)
158. Narvaiza I, Mazzolini G, Barajas M et al.: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164, 3112-3122 (2000). (Pubitemid 30148972)
159. Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J: Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8, 282-290 (2001). (Pubitemid 32237061)
160. Loetscher M, Gerber B, Loetscher P et al.: Chemokine receptor specific for IP10 and MIG: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184, 963-969 (1996).
161. Taub DD, Lloyd AR, Conlon K et al.: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177, 1809-1814 (1993).
162. Angiolillo AL, Sgadari C, Taub DD et al.: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155-162 (1995).
163. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005). (Pubitemid 40524630)
164. Huang H, Xiang J: Synergistic effect of lymphotactin and interferon γ-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int. J. Cancer 109, 817-825 (2004). (Pubitemid 38500737)
165. Emtage PC, Wan Y, Hitt M et al.: Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10, 697-709 (1999).
166. Del Vecchio M, Bajetta E, Canova S et al.: Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677-4685 (2007).
167. Rousseau RF, Haight AE, Hirschmann-Jax C et al.: Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101, 1718-1726 (2003). (Pubitemid 36237566)
168. Russell HV, Strother D, Mei Z et al.: Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J. Immunother. 30, 227-233 (2007). (Pubitemid 46667802)
169. Kershaw MH, Wang G, Westwood JA et al.: Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13, 1971-1980 (2002).